Novartis


Novartis on course to set new highs

20/02/24 -"Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV estimates by c.10%."

Pages
71
Language
English
Published on
20/02/24
You may also be interested by these reports :
07/02/25
The Q4 operating profitability was somewhat ahead of the street’s expectations, though sales lagged the consensus by c.2%. Moreover, the 2025 outlook ...

06/02/25
The Q4 results exceeded the street’s expectations, while the 2025 outlook was in line with consensus estimates. Moreover, the firm raised its ...

06/02/25
The Q4 sales were ahead of the consensus, though operating profits were somewhat behind the street’s expectations. Also, a better-than-expected 2025 ...

05/02/25
The Q4 earnings were ahead of consensus estimates, driven by a robust showing across key focus areas. Moreover, the 2025 outlook was better than the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO